Patents by Inventor Johan Neyts
Johan Neyts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12286423Abstract: The invention provides compounds of Formula (I): as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.Type: GrantFiled: April 20, 2021Date of Patent: April 29, 2025Assignees: Novartis AG, Katholieke Universiteit Leuven, Korea Research Institute of Chemical TechnologyInventors: Johan Neyts, Daniel Poon, Keith Bruce Pfister, Young-Sik Jung, Soo Bong Han, Yashwardhan R. Malpani, Prashant Chakrasali, Bishyajit Kumar Biswas, Chong-Kyo Lee, Chonsaeng Kim, Jin Soo Shin, Hae Soo Kim
-
Publication number: 20250099568Abstract: The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region. FIG. 1A.Type: ApplicationFiled: July 19, 2024Publication date: March 27, 2025Applicant: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Kai Dallmeier, Niraj Mishra, Johan Neyts, Lorena Senchez
-
Publication number: 20250090491Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.Type: ApplicationFiled: August 7, 2024Publication date: March 20, 2025Inventors: Johan NEYTS, Daniel POON, Keith Bruce PFISTER, Young-Sik JUNG, Soo Bong HAN, Yashwardhan R. MALPANI, Prashant CHAKRASALI, Sang-Ho LEE, Chong-Kyo LEE, Chonsaeng KIM, Jin Soo SHIN, Hae Soo KIM
-
Patent number: 12083092Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.Type: GrantFiled: April 20, 2021Date of Patent: September 10, 2024Assignees: Novartis AG, Katholieke Universiteit Leuven, Korea Research Institute of Chemical TechnologyInventors: Johan Neyts, Daniel Poon, Keith Bruce Pfister, Young-Sik Jung, Soo Bong Han, Yashwardhan R. Malpani, Prashant Chakrasali, Sang-Ho Lee, Chong-Kyo Lee, Chonsaeng Kim, Jin Soo Shin, Hae Soo Kim
-
Patent number: 12070494Abstract: The invention describes chimeric Flavivirus constructs comprising lyssavirus G proteins in the E/NS1 intergenic region.Type: GrantFiled: September 6, 2019Date of Patent: August 27, 2024Assignee: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Kai Dallmeier, Niraj Mishra, Johan Neyts, Lorena Sanchez
-
Patent number: 12012411Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: November 30, 2021Date of Patent: June 18, 2024Assignee: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
-
Publication number: 20240148909Abstract: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.Type: ApplicationFiled: January 5, 2024Publication date: May 9, 2024Inventors: Nesva GORIS, Johan NEYTS, Erwin BLOMSMA, Stefaan WERA, Ainola BILLIET, Joeri AUWERX, Veerle DEBEURME, Maryline ROE, Pascal PUIG
-
Patent number: 11904024Abstract: The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals.Type: GrantFiled: March 18, 2021Date of Patent: February 20, 2024Assignee: Aratana Therapeutics, Inc.Inventors: Nesya Goris, Johan Neyts, Erwin Blomsma, Stefaan Wera, Ainola Billiet, Joeri Auwerx, Veerle Debeurme, Maryline Roe, Pascal Puig
-
Publication number: 20230406889Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.Type: ApplicationFiled: May 5, 2023Publication date: December 21, 2023Applicant: Katholieke Universiteit LeuvenInventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
-
Publication number: 20230241201Abstract: The invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding the S1 and S2 subunits of a coronavirus Spike protein is located, such that a chimeric virus is expressed.Type: ApplicationFiled: March 1, 2021Publication date: August 3, 2023Inventors: Kai DALLMEIER, Johan NEYTS, Lorena SANCHEZ FELIPE, Hendrik, Jan THIBAUT, Dominique VAN LOOVEREN, Thomas VERCRUYSSE
-
Publication number: 20230227537Abstract: The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses.Type: ApplicationFiled: February 5, 2021Publication date: July 20, 2023Inventors: Bert SCHEPENS, Xavier SAELENS, Nico CALLEWAERT, Dorien DE VLIEGER, Loes VAN SCHIE, Wim NERINCKX, Kenny ROOSE, Wander VAN BREEDAM, Hannah EECKHAUT, Daria FIJALKOWSKA, Chiara LONIGRO, Sieglinde DE CAE, Bruno DOMBRECHT, Catelijne STORTELERS, Johan NEYTS, Leen DELANG, Suzanne KAPTEIN, Joana DUARTE DA ROCHA PEREIRA, Barney GRAHAM, Jason MCLELLAN, Daniel WRAPP, Han REMAUT
-
Patent number: 11680084Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.Type: GrantFiled: October 5, 2018Date of Patent: June 20, 2023Assignee: KATHOLIEKE UNIVERSITEIT LEUVENInventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
-
Patent number: 11566025Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: February 24, 2020Date of Patent: January 31, 2023Assignee: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Mohamed Koukni, Arnaud Marchand, Johan Neyts, Wim Smets
-
Publication number: 20220409583Abstract: The present invention relates to the use of substituted indole derivatives and substituted indoline derivatives in the manufacture of a medicament for the treatment of dengue disease in an individual infected by dengue virus or the prevention of dengue disease in an individual at risk of being infected by Dengue virus. The invention further provides a method for the treatment or the prevention of dengue in an individual at risk of being infected by Dengue virus.Type: ApplicationFiled: November 13, 2020Publication date: December 29, 2022Applicants: Janssen Pharmaceuticals, Inc., Katholieke Universiteit LeuvenInventors: Olivia Gabriella M. GOETHALS, Bart Rudolf Romanie KESTELEYN, Bart Henri Theresia STOOPS, Jean-François BONFANTI, Tim Hugo Maria JONCKERS, Marnix VAN LOOCK, Suzanne KAPTEIN, Johan NEYTS
-
Publication number: 20220402976Abstract: The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a Filovirus glycoprotein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order: a further signal peptide of a Flavivirus NS1 protein, a filovirus glycoprotein wherein the N terminal signal peptide is absent, a TM domain of a flaviviral E protein.Type: ApplicationFiled: September 4, 2020Publication date: December 22, 2022Inventors: Kai DALLMEIER, Lorena SANCHEZ FELIPE, Viktor LEMMENS, Johan NEYTS
-
Publication number: 20220378903Abstract: The present invention relates to polynucleotides comprising a sequence of a live, infectious, attenuated Flavivirus wherein a nucleotide sequence encoding at least a part of a arenavirus glycoprotein protein is located at the intergenic region between the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following order:—a further signal peptide of a Flavivirus NS1 protein,—an arenavirus Glycoprotein protein lacking the N terminal signal sequence and the GP2 transmembrane domain,—a TM1 and TM2 domain of a flaviviral E protein.Type: ApplicationFiled: September 11, 2020Publication date: December 1, 2022Inventors: Kai DALLMEIER, Viktor LEMMENS, Johan NEYTS, Lorena SANCHEZ FELIPE
-
Patent number: 11351240Abstract: The present invention relates to chimeric yellow fever—Zika strains and attenuated versions thereof, wherein the nucleotide sequence encoding the signal sequence and prME protein of said yellow virus is replaced by a nucleotide sequence encoding the signal sequence and the prME protein of a Zika virus.Type: GrantFiled: October 5, 2018Date of Patent: June 7, 2022Assignee: Katholieke Universiteit LeuvenInventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts, Michael Alexander Schmid
-
Publication number: 20220168412Abstract: A polynucleotide comprising the sequence of a live, infectious, attenuated Zika-Japanese encephalitis (JEV) chimeric virus wherein the nucleotide sequence encoding the prME protein of said Zika virus is replaced by a nucleotide sequence encoding the prME protein of a Japanese encephalitis virus, so that said prME protein of said Japanese encephalitis virus is expressed.Type: ApplicationFiled: April 10, 2020Publication date: June 2, 2022Inventors: Kai Dallmeier, Dieudonné Buh Kum, Niraj Mishra, Johan Neyts
-
Publication number: 20220106321Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: ApplicationFiled: November 30, 2021Publication date: April 7, 2022Applicant: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni
-
Patent number: 11279704Abstract: The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine to treat or prevent viral infections, particularly infections with RNA viruses, more particularly infections with viruses belonging to the family of the Flaviviridae, and yet more particularly infections with the Dengue virus. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of viral infections. The invention also relates to processes for preparation of the compounds.Type: GrantFiled: July 18, 2019Date of Patent: March 22, 2022Assignee: Katholieke Universiteit LeuvenInventors: Dorothée Bardiot, Gunter Carlens, Kai Dallmeier, Suzanne Kaptein, Michael McNaughton, Arnaud Marchand, Johan Neyts, Wim Smets, Mohamed Koukni